Q3 EPS Forecast for Promis Neurosciences Raised by Analyst

Promis Neurosciences (NASDAQ:PMN) – Equities researchers at HC Wainwright boosted their Q3 2026 earnings estimates for Promis Neurosciences in a research report issued to clients and investors on Monday, October 12th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings of ($0.98) per share for the quarter, up from their previous estimate of ($1.13). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Promis Neurosciences’ current full-year earnings is ($5.29) per share. HC Wainwright also issued estimates for Promis Neurosciences’ Q4 2026 earnings at ($0.86) EPS, FY2026 earnings at ($4.18) EPS, Q1 2027 earnings at ($0.68) EPS, Q2 2027 earnings at ($0.60) EPS, Q3 2027 earnings at ($0.65) EPS, Q4 2027 earnings at ($0.71) EPS and FY2027 earnings at ($2.63) EPS.

A number of other analysts also recently commented on PMN. Cantor Fitzgerald assumed coverage on shares of Promis Neurosciences in a research note on Tuesday, June 30th. They set an “overweight” rating for the company. Chardan Capital set a $20.00 target price on shares of Promis Neurosciences and gave the stock a “buy” rating in a report on Monday, July 27th. Guggenheim restated a “buy” rating and issued a $69.00 price target (up from $35.00) on shares of Promis Neurosciences in a research report on Tuesday, July 28th. Roth Capital set a $29.00 price target on shares of Promis Neurosciences in a research report on Friday, August 21st. Finally, Wall Street Zen raised Promis Neurosciences from a “strong sell” rating to a “sell” rating in a report on Saturday, July 18th. Two investment analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $34.00.

Promis Neurosciences Stock Down 8.4%

Shares of PMN opened at $8.66 on Wednesday. The firm’s 50 day moving average is $12.78 and its 200-day moving average is $12.13. Promis Neurosciences has a 12-month low of $6.27 and a 12-month high of $27.40.

Promis Neurosciences (NASDAQ:PMN) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($1.28) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.38) by $0.10.

Institutional Investors Weigh In On Promis Neurosciences

Hedge funds have recently modified their holdings of the stock. Seven Fleet Capital Management LP acquired a new position in shares of Promis Neurosciences in the 1st quarter valued at $135,000. ADAR1 Capital Management LLC purchased a new position in Promis Neurosciences in the 1st quarter worth about $1,211,000. Ally Bridge Group NY LLC increased its stake in Promis Neurosciences by 66.1% in the 1st quarter. Ally Bridge Group NY LLC now owns 414,219 shares of the company’s stock worth $5,261,000 after purchasing an additional 164,880 shares in the last quarter. Yu Fan acquired a new stake in Promis Neurosciences during the 1st quarter worth about $4,188,000. Finally, Janus Henderson Group PLC acquired a new stake in Promis Neurosciences during the 1st quarter worth about $16,418,000. 50.13% of the stock is owned by hedge funds and other institutional investors.

Promis Neurosciences Company Profile

ProMIS Neurosciences Inc (NASDAQ: PMN) is a clinical-stage biotechnology company focused on developing antibody-based treatments for neurodegenerative diseases. The company uses its proprietary technology platform to identify disease-related misfolded proteins and selectively target toxic forms that may contribute to neuronal damage.

ProMIS’s lead investigational product is PMN310, an antibody designed to target toxic soluble amyloid-beta oligomers associated with Alzheimer’s disease while avoiding healthier forms of amyloid-beta.